MCID: PDT021
MIFTS: 34

Pediatric Osteosarcoma

Categories: Bone diseases, Cancer diseases

Aliases & Classifications for Pediatric Osteosarcoma

MalaCards integrated aliases for Pediatric Osteosarcoma:

Name: Pediatric Osteosarcoma 12 15
Childhood Osteosarcoma 74

Classifications:



External Ids:

Disease Ontology 12 DOID:3361
NCIt 51 C6585
UMLS 74 C1332986

Summaries for Pediatric Osteosarcoma

MalaCards based summary : Pediatric Osteosarcoma, also known as childhood osteosarcoma, is related to methotrexate toxicity or dose selection and myelomeningocele. An important gene associated with Pediatric Osteosarcoma is SLC19A1 (Solute Carrier Family 19 Member 1), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Selenium Micronutrient Network. The drugs Cisplatin and Azacitidine have been mentioned in the context of this disorder. Affiliated tissues include bone, and related phenotypes are growth/size/body region and embryo

Related Diseases for Pediatric Osteosarcoma

Graphical network of the top 20 diseases related to Pediatric Osteosarcoma:



Diseases related to Pediatric Osteosarcoma

Symptoms & Phenotypes for Pediatric Osteosarcoma

MGI Mouse Phenotypes related to Pediatric Osteosarcoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.7 DHFR HK2 MTHFR RFC1 ROCK1 SLC19A1
2 embryo MP:0005380 9.65 DHFR HK2 RFC1 SLC19A1 SOX4
3 integument MP:0010771 9.35 DHFR MTHFR ROCK1 SLC19A1 SOX4
4 mortality/aging MP:0010768 9.17 DHFR HK2 MTHFR RFC1 ROCK1 SLC19A1

Drugs & Therapeutics for Pediatric Osteosarcoma

Drugs for Pediatric Osteosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 2,Not Applicable 15663-27-1 441203 84093 2767
2
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
3
nivolumab Approved Phase 1, Phase 2 946414-94-4
4 Pharmaceutical Solutions Phase 2
5 Antimetabolites, Antineoplastic Phase 1, Phase 2,Not Applicable
6 Antimetabolites Phase 1, Phase 2,Not Applicable
7 Antineoplastic Agents, Immunological Phase 1, Phase 2
8
Carboplatin Approved Not Applicable 41575-94-4 38904 10339178 498142
9
Mesna Approved, Investigational Not Applicable 3375-50-6 598
10
Ifosfamide Approved Not Applicable 3778-73-2 3690
11
Methotrexate Approved Not Applicable 1959-05-2, 59-05-2 126941
12
Doxorubicin Approved, Investigational Not Applicable 23214-92-8 31703
13
Gemcitabine Approved Not Applicable 95058-81-4 60750
14
Mechlorethamine Approved, Investigational Not Applicable 51-75-2 4033
15
leucovorin Approved Not Applicable 58-05-9 6006 143
16
Sargramostim Approved, Investigational Not Applicable 123774-72-1, 83869-56-1
17
Folic Acid Approved, Nutraceutical, Vet_approved Not Applicable 59-30-3 6037
18
Doxil Approved June 1999 Not Applicable 31703
19 Vitamin B Complex Not Applicable
20 Anti-Infective Agents Not Applicable
21 Immunosuppressive Agents Not Applicable
22
Isophosphamide mustard Not Applicable 0
23 Anti-Bacterial Agents Not Applicable
24 Antineoplastic Agents, Alkylating Not Applicable
25 Antiviral Agents Not Applicable
26 Folate Not Applicable
27 Vitamin B9 Not Applicable
28 Immunologic Factors Not Applicable
29 Nucleic Acid Synthesis Inhibitors Not Applicable
30 Topoisomerase Inhibitors Not Applicable
31 Alkylating Agents Not Applicable
32 Antibiotics, Antitubercular Not Applicable
33 Antimitotic Agents Not Applicable
34 Cardiotonic Agents Not Applicable
35 Protective Agents Not Applicable
36 Antirheumatic Agents Not Applicable
37 Folic Acid Antagonists Not Applicable
38 Dermatologic Agents Not Applicable
39 razoxane Not Applicable

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors Recruiting NCT02581384 Phase 1, Phase 2
2 Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma Active, not recruiting NCT01650090 Phase 2 Inhaled Lipid Cisplatin (ILC)
3 Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma Not yet recruiting NCT03628209 Phase 1, Phase 2 Nivolumab;Azacitidine
4 Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity Recruiting NCT03139318 Not Applicable
5 The Impact of Cancer on the Physical and Psychosocial Well-being Among Childhood Osteosarcoma Survivors Recruiting NCT03298971
6 Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy Terminated NCT00673179 Not Applicable Doxorubicin;Cisplatin;Methotrexate;Leucovorin;Dexrazoxane;Ifosfamide;Gemcitabine;Sargramostim;Mesna

Search NIH Clinical Center for Pediatric Osteosarcoma

Genetic Tests for Pediatric Osteosarcoma

Anatomical Context for Pediatric Osteosarcoma

MalaCards organs/tissues related to Pediatric Osteosarcoma:

42
Bone

Publications for Pediatric Osteosarcoma

Articles related to Pediatric Osteosarcoma:

(show top 50) (show all 105)
# Title Authors Year
1
Pediatric Osteosarcoma of Extremities: A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt. ( 30629005 )
2019
2
Educational Case: Pediatric Osteosarcoma. ( 30859126 )
2019
3
Downregulated Adhesion-Associated microRNAs as Prognostic Predictors in Childhood Osteosarcoma. ( 28944406 )
2019
4
miRa89188 suppresses tumor progression by targeting SOX4 in pediatric osteosarcoma. ( 29749512 )
2018
5
Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study. ( 29357275 )
2018
6
Biological function of microRNA-30c/SOX9 in pediatric osteosarcoma cell growth and metastasis. ( 29364496 )
2018
7
Carbon ion radiotherapy for inoperable pediatric osteosarcoma. ( 29796166 )
2018
8
The Effect of Clown Intervention on Self-Report and Biomarker Measures of Stress and Fatigue in Pediatric Osteosarcoma Inpatients: A Pilot Study. ( 29900751 )
2018
9
Two HLA Class II Gene Variants Are Independently Associated with Pediatric Osteosarcoma Risk. ( 30038050 )
2018
10
Clinically relevant concentration of anti-viral drug ribavirin selectively targets pediatric osteosarcoma and increases chemosensitivity. ( 30454696 )
2018
11
Growth of epiphysis after epiphyseal-preservation surgery for childhood osteosarcoma around the knee joint. ( 29875014 )
2018
12
The Efficiency and Toxicity of Mifamurtide in Childhood Osteosarcoma. ( 29889801 )
2018
13
TRIM37 promotes tumor cell proliferation and drug resistance in pediatric osteosarcoma. ( 29163677 )
2017
14
Ambulatory High-dose Methotrexate Administration in Pediatric Osteosarcoma Patients at a Single Institution in Argentina. ( 28937522 )
2017
15
Pediatric Osteosarcoma: An Updated Review. ( 28469335 )
2017
16
Quantitative diffusion-weighted magnetic resonance imaging assessment of chemotherapy treatment response of pediatric osteosarcoma and Ewing sarcoma malignant bone tumors. ( 28806574 )
2017
17
The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients. ( 28592186 )
2017
18
Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report. ( 29390436 )
2017
19
The expression and function of miRNA-106 in pediatric osteosarcoma. ( 28272712 )
2017
20
Immunotherapeutic approaches in pediatric osteosarcoma. ( 28353326 )
2017
21
ATIC Gene Polymorphism and Histologic Response to Chemotherapy in Pediatric Osteosarcoma. ( 28267080 )
2017
22
Childhood osteosarcoma: Incidence and survival in Argentina. Report from the National Pediatric Cancer Registry, ROHA Network 2000-2013. ( 28409896 )
2017
23
Pharmacological or genetic inhibition of LDHA reverses tumor progression of pediatric osteosarcoma. ( 27261617 )
2016
24
CUL4A expression in pediatric osteosarcoma tissues and its effect on cell growth in osteosarcoma cells. ( 26715273 )
2016
25
Multimodality Imaging in Pediatric Osteosarcoma in the Era of Image Gently and Image Wisely Campaign With a Close Look at the CT Scan Radiation Dose. ( 26583624 )
2016
26
Novel insights and therapeutic interventions for pediatric osteosarcoma. ( 27651036 )
2016
27
Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma. ( 27104192 )
2016
28
The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma. ( 26603261 )
2016
29
Efficacy of pamidronate in pediatric osteosarcoma patients with low bone mineral density. ( 27104175 )
2016
30
Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma. ( 26583357 )
2016
31
Bone mineral density change during adjuvant chemotherapy in pediatric osteosarcoma. ( 26512351 )
2015
32
PI3K/Akt signaling mediated Hexokinase-2 expression inhibits cell apoptosis and promotes tumor growth in pediatric osteosarcoma. ( 26116768 )
2015
33
Experience of Pediatric Osteosarcoma of the Extremity at a Single Institution in Taiwan: Prognostic Factors and Impact on Survival. ( 25323470 )
2014
34
Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma. ( 24038809 )
2014
35
Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: a case series and review of the literature. ( 24667129 )
2014
36
In silico functional analyses and discovery of survival-associated microRNA signatures in pediatric osteosarcoma. ( 25594070 )
2014
37
Management of local recurrence of pediatric osteosarcoma following limb-sparing surgery. ( 24558066 )
2014
38
Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. ( 25520112 )
2014
39
Pediatric Osteosarcoma: A Single Institution's Experience. ( 25365431 )
2014
40
Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. ( 24703847 )
2014
41
Long-term pulmonary function after metastasectomy for childhood osteosarcoma: a report from the St Jude lifetime cohort study. ( 24795268 )
2014
42
Successful management of a childhood osteosarcoma with epiphysiolysis and distraction osteogenesis. ( 25089114 )
2014
43
Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand. ( 23621194 )
2013
44
Bronchioloalveolar carcinoma as a second malignancy in a pediatric osteosarcoma survivor: case report. ( 23758793 )
2013
45
Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. ( 23430441 )
2013
46
Endothelin-1 gene polymorphisms and risk of chemoresistant pediatric osteosarcoma. ( 24123836 )
2013
47
Combined MicroRNA-340 and ROCK1 mRNA Profiling Predicts Tumor Progression and Prognosis in Pediatric Osteosarcoma. ( 24398981 )
2013
48
Pathological fracture as the presenting feature in pediatric osteosarcoma. ( 23281226 )
2013
49
Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma. ( 22652833 )
2012
50
Correlation of non-mass-like abnormal MR signal intensity with pathological findings surrounding pediatric osteosarcoma and Ewing's sarcoma. ( 22406919 )
2012

Variations for Pediatric Osteosarcoma

Expression for Pediatric Osteosarcoma

Search GEO for disease gene expression data for Pediatric Osteosarcoma.

Pathways for Pediatric Osteosarcoma

Pathways related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.04 DHFR MTHFR SLC19A1
2
Show member pathways
11.67 DHFR MTHFR SLC19A1
3
Show member pathways
11.28 ATIC DHFR MTHFR
4 10.42 ATIC DHFR MTHFR SLC19A1

GO Terms for Pediatric Osteosarcoma

Biological processes related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metabolic process GO:0008152 9.54 ATIC HK2 MTHFR
2 DNA damage response, detection of DNA damage GO:0042769 9.4 RFC1 SOX4
3 one-carbon metabolic process GO:0006730 9.32 DHFR MTHFR
4 tetrahydrofolate metabolic process GO:0046653 9.26 DHFR MTHFR
5 tetrahydrofolate biosynthetic process GO:0046654 9.16 ATIC DHFR
6 dihydrofolate metabolic process GO:0046452 8.96 ATIC DHFR
7 folic acid metabolic process GO:0046655 8.8 DHFR MTHFR SLC19A1

Molecular functions related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 catalytic activity GO:0003824 9.33 ATIC HK2 MTHFR
2 NADP binding GO:0050661 8.96 DHFR MTHFR
3 folic acid binding GO:0005542 8.62 DHFR SLC19A1

Sources for Pediatric Osteosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....